Single agent vandetanib was found to induce tumor regression in vivo in TNBC patient-derived xenograft models with tumors that expressed high levels of EGFR [16] and showed clinical promise as an anti-proliferative agent in breast cancer in a small clinical trial (NCT01934335), although the sample size was very small. Here, EGFR is linked to breast carcinoma.